Cargando…

The Safe Use of (125)I-Seeds as a Localization Technique in Breast Cancer during Pregnancy

SIMPLE SUMMARY: The results of this multidisciplinary study can function as a clinician’s guide for determining the preferred surgical localization technique for breast-conserving surgery in pregnant women with breast cancer and its timing, without avoiding the use of a (125)I-seed. The maximum expo...

Descripción completa

Detalles Bibliográficos
Autores principales: Heeling, Eva, van de Kamer, Jeroen B., Methorst, Michelle, Bruining, Annemarie, van de Meent, Mette, Vrancken Peeters, Marie-Jeanne T. F. D., Lok, Christianne A. R., van der Ploeg, Iris M. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296371/
https://www.ncbi.nlm.nih.gov/pubmed/37370839
http://dx.doi.org/10.3390/cancers15123229
_version_ 1785063642347077632
author Heeling, Eva
van de Kamer, Jeroen B.
Methorst, Michelle
Bruining, Annemarie
van de Meent, Mette
Vrancken Peeters, Marie-Jeanne T. F. D.
Lok, Christianne A. R.
van der Ploeg, Iris M. C.
author_facet Heeling, Eva
van de Kamer, Jeroen B.
Methorst, Michelle
Bruining, Annemarie
van de Meent, Mette
Vrancken Peeters, Marie-Jeanne T. F. D.
Lok, Christianne A. R.
van der Ploeg, Iris M. C.
author_sort Heeling, Eva
collection PubMed
description SIMPLE SUMMARY: The results of this multidisciplinary study can function as a clinician’s guide for determining the preferred surgical localization technique for breast-conserving surgery in pregnant women with breast cancer and its timing, without avoiding the use of a (125)I-seed. The maximum exposure to the fetus remains well below 100 millisieverts (mSv), the threshold value for tissue damage caused by radiation. If the exposure should remain below 1 mSv, the implantation and surgical removal of the (125)I-seed should occur within two weeks after a GA of 26 weeks, and within one week after a GA of 32 weeks. The contribution of an axillary seed is negligible (at maximum, 2.3% of the seed implanted in the breast). ABSTRACT: Introduction: Some aspects of the treatment protocol for breast cancer during pregnancy (PrBC) have not been thoroughly studied. This study provides clarity regarding the safety of the use of (125)I-seeds as a localization technique for breast-conserving surgery in patients with PrBC. Methods: To calculate the exposure to the fetus of one (125)I-seed implanted in a breast tumor, we developed a model accounting for the decaying (125)I-source, time to surgery, and the declining distance between the (125)I-seed and the fetus. The primary outcome was the maximum cumulative fetal dose of radiation at consecutive gestational ages (GA). Results: The cumulative fetal dose remains below 1 mSv if a single (125)I-seed is implanted at a GA of 26 weeks. After a GA of 26 weeks, the fetal dose can be at a maximum of 11.6 mSv. If surgery takes place within two weeks of implantation from a GA of 26 weeks, and one week above a GA of 32 weeks, the dose remains below 1 mSv. Conclusion: The use of (125)I-seeds is safe in PrBC. The maximum fetal exposure remains well below the threshold of 100 mSv, and therefore, does not lead to an increased risk of fetal tissue damage. Still, we propose keeping the fetal dose as low as possible, preferably below 1 mSv.
format Online
Article
Text
id pubmed-10296371
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102963712023-06-28 The Safe Use of (125)I-Seeds as a Localization Technique in Breast Cancer during Pregnancy Heeling, Eva van de Kamer, Jeroen B. Methorst, Michelle Bruining, Annemarie van de Meent, Mette Vrancken Peeters, Marie-Jeanne T. F. D. Lok, Christianne A. R. van der Ploeg, Iris M. C. Cancers (Basel) Article SIMPLE SUMMARY: The results of this multidisciplinary study can function as a clinician’s guide for determining the preferred surgical localization technique for breast-conserving surgery in pregnant women with breast cancer and its timing, without avoiding the use of a (125)I-seed. The maximum exposure to the fetus remains well below 100 millisieverts (mSv), the threshold value for tissue damage caused by radiation. If the exposure should remain below 1 mSv, the implantation and surgical removal of the (125)I-seed should occur within two weeks after a GA of 26 weeks, and within one week after a GA of 32 weeks. The contribution of an axillary seed is negligible (at maximum, 2.3% of the seed implanted in the breast). ABSTRACT: Introduction: Some aspects of the treatment protocol for breast cancer during pregnancy (PrBC) have not been thoroughly studied. This study provides clarity regarding the safety of the use of (125)I-seeds as a localization technique for breast-conserving surgery in patients with PrBC. Methods: To calculate the exposure to the fetus of one (125)I-seed implanted in a breast tumor, we developed a model accounting for the decaying (125)I-source, time to surgery, and the declining distance between the (125)I-seed and the fetus. The primary outcome was the maximum cumulative fetal dose of radiation at consecutive gestational ages (GA). Results: The cumulative fetal dose remains below 1 mSv if a single (125)I-seed is implanted at a GA of 26 weeks. After a GA of 26 weeks, the fetal dose can be at a maximum of 11.6 mSv. If surgery takes place within two weeks of implantation from a GA of 26 weeks, and one week above a GA of 32 weeks, the dose remains below 1 mSv. Conclusion: The use of (125)I-seeds is safe in PrBC. The maximum fetal exposure remains well below the threshold of 100 mSv, and therefore, does not lead to an increased risk of fetal tissue damage. Still, we propose keeping the fetal dose as low as possible, preferably below 1 mSv. MDPI 2023-06-17 /pmc/articles/PMC10296371/ /pubmed/37370839 http://dx.doi.org/10.3390/cancers15123229 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Heeling, Eva
van de Kamer, Jeroen B.
Methorst, Michelle
Bruining, Annemarie
van de Meent, Mette
Vrancken Peeters, Marie-Jeanne T. F. D.
Lok, Christianne A. R.
van der Ploeg, Iris M. C.
The Safe Use of (125)I-Seeds as a Localization Technique in Breast Cancer during Pregnancy
title The Safe Use of (125)I-Seeds as a Localization Technique in Breast Cancer during Pregnancy
title_full The Safe Use of (125)I-Seeds as a Localization Technique in Breast Cancer during Pregnancy
title_fullStr The Safe Use of (125)I-Seeds as a Localization Technique in Breast Cancer during Pregnancy
title_full_unstemmed The Safe Use of (125)I-Seeds as a Localization Technique in Breast Cancer during Pregnancy
title_short The Safe Use of (125)I-Seeds as a Localization Technique in Breast Cancer during Pregnancy
title_sort safe use of (125)i-seeds as a localization technique in breast cancer during pregnancy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296371/
https://www.ncbi.nlm.nih.gov/pubmed/37370839
http://dx.doi.org/10.3390/cancers15123229
work_keys_str_mv AT heelingeva thesafeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT vandekamerjeroenb thesafeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT methorstmichelle thesafeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT bruiningannemarie thesafeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT vandemeentmette thesafeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT vranckenpeetersmariejeannetfd thesafeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT lokchristiannear thesafeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT vanderploegirismc thesafeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT heelingeva safeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT vandekamerjeroenb safeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT methorstmichelle safeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT bruiningannemarie safeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT vandemeentmette safeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT vranckenpeetersmariejeannetfd safeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT lokchristiannear safeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy
AT vanderploegirismc safeuseof125iseedsasalocalizationtechniqueinbreastcancerduringpregnancy